

Streptococcus Group A (5E439): sc-73073

BACKGROUND

The *Streptococcus* bacterium exists in more than 20 serologic groups, based on differences in group-specific polysaccharides located in the bacterial cell wall. The groups are designated by letters. *Streptococcus* Group A (GAS) is a Gram-positive, non-spore-forming, non-motile organism that appears as pairs of short chains. *Streptococcus* Group A bacterium are responsible for most cases of streptococcal illness. Other groups (B, C, D and G) may also cause infection. Found to inhabit a wide range of hosts including humans, horses, pigs and cows, *Streptococci* colonize the mucosal surfaces of the mouth, nose and pharynx. Severe GAS infections may lead not only to shock and multi-system organ failure, but also to death. Early recognition and treatment with the antibiotics of choice, penicillin, erythromycin and clindamycin, is critical. *Streptococcus* Group A causes a wide range of illness, from mild sore throats to life-threatening invasive disease.

REFERENCES

1. Amir, J., Rotman, M., Schwartz, K., Maayan, R. and Varsano, I. 1994. Evaluation of a rapid test to detect *Streptococcus* Group A. *Isr. J. Med. Sci.* 30: 617-619.
2. Kreis, U.C., Varma, V. and Pinto, B.M. 1995. Application of two-dimensional NMR spectroscopy and molecular dynamics simulations to the conformational analysis of oligosaccharides corresponding to the cell-wall polysaccharide of *Streptococcus* Group A. *Int. J. Biol. Macromol.* 17: 117-130.
3. Weimar, T., Harris, S.L., Pitner, J.B., Bock, K. and Pinto, B.M. 1995. Transferred nuclear Overhauser enhancement experiments show that the monoclonal antibody strep 9 selects a local minimum conformation of a *Streptococcus* Group A trisaccharide-hapten. *Biochemistry* 34: 13672-13681.
4. Stuike-Prill, R. and Pinto, B.M. 1995. Conformational analysis of oligosaccharides corresponding to the cell-wall polysaccharide of the *Streptococcus* Group A by Metropolis Monte Carlo simulations. *Carbohydr. Res.* 279: 59-73.
5. Auzanneau, F.I., Foroughian, F. and Pinto, B.M. 1996. Efficient, convergent syntheses of oligosaccharide allyl glycosides corresponding to the *Streptococcus* Group A cell-wall polysaccharide. *Carbohydr. Res.* 291: 21-41.
6. Chelsom, J. and Halstensen, A. 2002. *Streptococcus* Group A infections of skin, soft tissue and blood. *Tidsskr. Nor. Laegeforen.* 121: 3310-3314.
7. Gonzalez-Rey, C., Belin, A.M., Jorbeck, H., Norman, M., Krovacek, K., Henriques, B., Kallenius, G. and Svenson, S.B. 2003. RAPD-PCR and PFGE as tools in the investigation of an outbreak of β -haemolytic *Streptococcus* Group A in a Swedish hospital. *Comp. Immunol. Microbiol. Infect. Dis.* 26: 25-35.
8. Braitto, A., Galgani, I., Mohammed, M.R., Iozzi, C., Ame, S.M., Haji, H.S. and Zanchi, A. 2004. Epidemiology of *Streptococcus* Group A in school aged children in Pemba. *East Afr. Med. J.* 81: 307-312.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

Streptococcus Group A (5E439) is a mouse monoclonal antibody raised against *Streptococcus* Group A.

PRODUCT

Each vial contains 100 μ g IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Streptococcus Group A (5E439) is recommended for detection of Group A *Streptococcus* by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.